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Abstract
Background: There is considerable interest in the use of cannabinoids for symptom control in palliative care,
but there is little high-quality evidence to guide clinical practice.
Objectives: Assess the feasibility of using global symptom burden measures to assess response to medicinal
cannabis, to determine median tolerated doses of cannabidiol (CBD) and tetrahydrocannabinol (THC), and to
document adverse events (AEs).
Design: Prospective two-arm open-label pilot trial of escalating doses of CBD and THC oil.
Setting/Subjects: Participants had advanced cancer and cancer-related symptoms in a palliative and supportive
care service in an Australian cancer center.
Measurements: The main outcome measures were the number of participants screened and randomized over the time
frame, the number of participants completing days 14 and 28 and providing total symptom distress scores (TSDSs)
(measured using the Edmonton Symptom Assessment Scale), and the change from baseline of the TSDS at day 14.
Results: Of the 21 participants enrolled (CBD, n = 16; THC, n = 5), 18 (86%) completed the primary outcome
measure at day 14 and 8 completed at day 28. The median maximum tolerated doses were CBD, 300 mg/day
(range 100–600 mg); THC, 10 mg/day (range 5–30 mg). Nine of 21 patients (43%) met the definition of
response (‡6 point reduction in TSDS). Drowsiness was the most common AE.
Conclusions: Trials of medicinal cannabis in advanced cancer patients undergoing palliative care are feasible. The
doses of THC and CBD used in this study were generally well tolerated and the outcome measure of total symptom
distress is promising as a measure of overall symptom benefit. Trial registration: ACTRN12618001205224.
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Introduction
Despite recent advances in medicine care, some pa-tients with advanced cancer still experience substantial
symptom distress.1 To improve symptom control and quality
of life (QoL), palliative care aims to provide a holistic indi-
vidualized approach to medical care. Some symptoms can be
difficult to control and there is a need for more effective
medications to assist with symptom management.
Medicinal cannabis may have potential to play an important
role in symptom control. Cannabis contains *500 bioactive
compounds, including *70 different cannabinoids.2 The pre-
dominant cannabinoids include delta-9-tetrahydrocannabinol
(THC) and cannabidiol (CBD). Although there is considerable
interest in the use of cannabinoids for symptom control in
palliative care, particularly among consumers, there is little
high-quality evidence to guide clinical practice.3 Despite the
very strong impression of benefit from the lay community,
reviews of benefit in the palliative care population have raised
many unknowns, for example, what is the ideal product, dose,
formulation, and clinical areas of benefit.
As studies of medicinal cannabis that have assessed iso-
lated symptoms in cancer patents have been largely negative,
for example, in pain and anorexia,4,5 this pilot study was
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designed to determine the feasibility of assessing symptom
burden as a whole, aiming to capture the perceived im-
provement in general well-being reported anecdotally by
many patients who have used cannabis.6,7 Symptom burden
was measured by using the Edmonton Symptom Assessment
Scale (ESAS).8
In this feasibility study, both CBD and THC were piloted
as single agents before definitive randomized placebo con-
trolled trials of various medicinal cannabis products. Sec-
ondary outcomes included dose tolerance, efficacy, patient-
perceived benefit, and adverse events (AEs).
Methods
This is a prospective two-arm open label trial of escalating
doses of CBD and THC oil (ACTRN12618001220257).
Limited supplies of both approved CBD and THC from
companies prepared to support cannabis research restricted
number of participants. The choice of study drug was at the
discretion of the patient and investigator based on factors
including patient preference, product availability, and gov-
ernment regulations prohibiting driving on THC. The study
was approved by the Mater Human Research Ethics Com-
mittee (HREC/18/MHS/83).
Population
Patients with advanced cancer and cancer-related symp-
toms were recruited from the palliative and supportive care
service within Mater Health Services in Brisbane. All par-
ticipants were receiving standard palliative care,9 and their
current medications were continued and modified according
to clinical need. Participants were reviewed each week in an
outpatient clinic, assessed for response and AEs, and pro-
vided with a new medication supply if appropriate.
Inclusion criteria
Patients aged >25 years with advanced cancer (metastatic
or locally advanced solid tumors or advanced hematological
malignancies) who had been referred or known to the palli-
ative care team, who had an ESAS total symptom distress
score (TSDS) ‡10 and at least one individual ESAS score ‡3,
a performance status AKPS (Australia-modified Karnofsky
Scale score) of ‡30 or above, and agreed to use no other
cannabis-based product/s for the duration of the trial were
eligible.
Exclusion criteria
Patients were excluded if they had a history of hypersen-
sitivity to any cannabinoid, unstable untreated cardiovascular
disease, severe hepatic or renal impairment, a history of
psychiatric disorders, cognitive impairment, known sub-
stance use disorder, or a history suggesting that drug diver-
sion may be a risk. Patients could not have participated in a
trial of a new clinical entity within the past 28 days, nor had
treatment with a new specific anticancer agent within the
previous 21 days or radiation therapy within 7 days.
Medications
Patients were allocated to either of two arms: Arm 1—
CBD (CBD 100 mg/mL) oral oily solution—dose range 50 to
600 mg/day, Arm 2—THC (Delta-9-THC 10 mg/mL) oral
oily solution—dose range 2.5 to 30 mg/day. The good
manufacturing practice approved products GD Cann-C
and Cann-T were supplied by GD Pharma who had no role
in the design of the trial nor interpretation of results. Dose
titration was monitored by regular consultation between
participant and trial clinicians. Participants were advised to
increase their dose every two days according to a set schedule
(Supplementary Appendix 1) until they were satisfied with
their symptom improvement or they experienced unaccept-
able side effects. They were then advised to remain on that
dose until the primary outcome point (14 days) and were
encouraged to remain on the cannabinoid preparation for
continuing assessment of efficacy and AEs for a total of
28 days. Post trial, participants were prescribed medicinal
cannabinoid preparations for on-going use if they chose to
continue.
Study outcomes
The primary outcome measure was feasibility as measured
by the number of participants screened, number and reason of
screen fails, number of participants completing 14 and
28 days, and ability to complete TSDS measurements over
time.
Symptom burden was measured by using the ESAS
TSDS.8 Nine symptoms are scored on a numerical rating
scale from 0 to 10 (0 = not a problem, 10 = worst possible).
Symptom burden can be represented by the physical scores
(sum of pain, fatigue, nausea, drowsiness, appetite, and
dyspnea), emotional scores (sum of depression and anxiety),
and the well-being score. TSDS is the sum of the physical,
emotional scores, and the well-being score. It ranges from 0
to 90, with a higher score representing higher symptom
burden. An improvement of 5.7 on the TSDS has been shown
to be the minimal clinical important difference.8
Secondary outcomes were patient-determined effective
doses of THC and CBD (defined as the dose that achieved
symptom relief with acceptable side effects), individual, to-
tal, physical, and emotional ESAS scores on medical review
days (days 7, 14, 21, and 28). Patient and clinician impression
of benefit was assessed using patient and clinician global
impression of change scales (PGIC and CGIC),10,11 along
with a depression, anxiety, and stress scale (DASS-2112) and
QoL (EORTC QLQ-C15-PAL13).
AEs were assessed using the National Cancer Institute
(NCI) common toxicity criteria.14 The known common AEs
associated with cannabinoids were specifically addressed at
each time point, namely neurological (confusion and som-
nolence), psychiatric (personality change, paranoia, anxiety,
mood changes, and psychosis), cardiovascular (hypertension
and tachycardia), systemic (sweating), and gastrointestinal
(nausea, vomiting, and abdominal pain) events.
Analysis and sample size
Descriptive analyses and frequency distributions were
generated from participants’ demographic and clinical char-
acteristics. Unless otherwise indicated, summary statistics
are reported as mean, standard deviation (SD) or mean,
standard error for normally distributed data, and as median,
interquartile range, or median and range for non-normally
distributed data. In preparation for an adequately powered
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randomized controlled trial, we defined response as a ‡6
point reduction in TSDS at day 14.8 TSDS and components of
ESAS at day 14 were compared with baseline using a paired
t test. Other comparisons were made using a paired t test
for normally distributed data and Wilcoxon’s rank sum test
for non-normally distributed data. Median survival was
estimated using the Kaplan–Meier product limit method.
Statistical significance was set at p £ 0.05. Participants were
constituted of a convenience sample. Sample size in this
study was limited by availability of the medications supplied.
Study data were entered into a custom-built REDCap da-
tabase (https://www.project-redcap.org) and analyzed using
Stata 13 StataCorp. 2013. Stata Statistical Software: Release
13. College Station, TX: StataCorp LP).
Results
Feasibility
Patient flow is shown in Figure 1. Thirty-three people were
approached to participate in the study, 27 were screened for
eligibility and 21 subjects consented to trial either CBD
(n = 16) or THC (n = 5) for a four-month time period. Eigh-
teen participants completed the primary outcome measure
(TSDSs) on day 14 (3 withdrawals, 1 on THC) and a further
10 participants (62% of total, 4 on THC) withdrew by day 28.
Reasons for withdrawal were noncompliance (2/21), unac-
ceptable side effects (1/21, drowsiness), and clinical deteri-
oration (6/21). Four participants withdrew consent. Three
participants requested ongoing medicinal cannabis poststudy.
Participant characteristics
The baseline characteristics of participants are given in
Table 1. The majority of participants were female (14/21).
Most participants had breast cancer as their primary diag-
nosis. Four of 21 participants tested positive for THC on the
urine cannabis pretrial screen (Table 1). All but one partici-
pant (20/21) were on an opioid medication at some stage
during the study, 8/21 were taking benzodiazepines, and 9/21
were on corticosteroids. The average number of medications
per participant was seven. All were receiving standard care
from the palliative care team. The median performance status
at baseline was 70/100 (range 50–90). The median survival
from start of study was 143 days (95% CI 57 days—not
estimable) at the census point (4 months after completion of
the last participant); six participants died within 1 month of
study completion.
Dose tolerance
The median maximum tolerated dose of CBD was 300 mg/
day (range 100–600 mg) whereas the median maximum tol-
erated dose of THC was 10 mg/day (range 5–30 mg).
Response
Nine of 21 patients (43%) met the definition of response
(>6 point reduction in TSDS). One participant on CBD had a
dramatic improvement in TSDS (-40 points) and seven re-
ported worsening symptom scores (Fig. 2).
Across all patients, there was no significant change in
ESAS TSDS from baseline to day 14 (mean [SD] change =
-5.8 [14.7], n = 18, p = 0.11). There was no improvement in
the physical subscale of ESAS (mean [SD] change = -2.6
[8.7], n = 18, p = 0.23) or well-being score (mean [SD]
change = -0.3 [2.6], n = 18, p = 0.65). There was a significant
improvement on the emotional subscale (mean [SD]
change = -2.9 [4.6], n = 18, p = 0.01).
FIG. 1. Consort diagram.
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The individual symptoms showing the greatest improve-
ment from baseline were anxiety, depression, and appetite
(Table 2).
The median (range) oral morphine equivalent (OME)
opioid dose at baseline was 140 mg/day (range 0–800, n = 21)
and 95 mg/day (0–370, n = 18) at day 14. In the 18 partici-
pants who completed day 14, there was no change in OME
between baseline and day 14 (median [range] 100 mg/day
[range 0–420] at baseline and 95 mg/day [range 0–370] at day
14, p = 0.09).
Impression of benefit, anxiety/depression, and QoL
At day 14, 8 of 18 (44.4%) participants reported a PGIC
score of 4 or more—reflecting an overall improvement in
their condition since starting cannabis. The remainder re-
ported no change or that their condition was worse. The
clinician-assessed CGIC at day 14 scored 50% of patients as
having had some improvement in their condition, with the
remainder having no change or worse.
For the 17 participants who completed the DASS-21 at day
14, the median (range) depression score decreased from 3 (0–
11) at baseline to 2 (0–18) at day 14, p = 0.04, with the median
stress score decreasing from 6 (0–21) at baseline to 3 (0–20)
at day 14, p = 0.046. The median anxiety score did not have a
significant change. The total median DASS scores decreased
from 13 (2–40) to 8 (0–50), p = 0.047. There was no change in
overall QoL as measured by the EORTC.
Adverse events
The most common AEs reported as worse than baseline at
any stage during the study were drowsiness, worsening mood,
hypertension, nausea/vomiting, and abdominal pain (Table 3).
No AE greater than grade 2 was reported.
Discussion
This pilot study was designed to assess feasibility of using
global symptom burden measures to assess response to me-
dicinal cannabis, to determine median tolerated doses of CBD
and THC, and to document AEs in preparation for a series
of randomized controlled trials of CBD, THC, and their
Table 1. Baseline Characteristics (n = 21)
Sex, male/female % 33.3/66.7
Age, mean (SD) 57.5 (12.4) years







AKPS (median, range) 70 (50–90)
TSDS (mean, SD, range) 41.1 (16.52, 14–64)






Bone/soft tissue 1 (5)












(from start of study)
143 days (95% CI 57 days—
not estimable)
CBD, cannabidiol; OME, oral morphine equivalent; SD, standard
deviation; THC, tetrahydrocannabinol; TSDS, total symptom distress
score.
FIG. 2. Waterfall plot of response per patient (n = 18) at day 14. The lower horizontal line represents a change in TSDS of
-6, the defined primary endpoint of the study. TSDS, total symptom distress score.
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combinations. It was not powered to measure efficacy, with the
sample size being dependant on product supplies available.
We confirmed feasibility in that participants were recruited
within a short time period, and 86% were able to complete the
primary outcome measure at day 14. The mean reduction in
TSDS of 5.8 at day 14 in this study is consistent with that
shown by Hui et al.8 when measuring symptom improvement
and suggests that our chosen outcome measure is appropriate.
A response rate of just <50% is perhaps less than would have
been anticipated in an open label study considering the an-
ticipated placebo effect. An interesting finding was the im-
provement in emotional ESAS scores. Whether this was a
consequence of trial participation and regular follow-up or of
medicinal cannabis is unknown and can only be confirmed
within the context of a larger placebo-controlled trial.
The majority of patients received the CBD product with a
median end dose of 300 mg/day. CBD has been predomi-
nately studied in refractory childhood epilepsies using doses
of 20 mg/kg.15 This is one of the first trials to study higher
dose CBD products in advanced cancer patients. The medi-
cation was generally well tolerated, the major adverse effect
being drowsiness that seemed dose related and improved with
a dose reduction. The adverse effect profile is consistent with
other studies in highlighting drowsiness and nausea.4 In some
patients, CBD appeared to lead to a marked improvement in
total symptom distress, whereas others had no discernible
benefit. The number of patients in this study receiving THC
was too small to make any meaningful conclusions.
This study protocol is novel in that it assesses total
symptom distress rather than individual symptoms. In a re-
cent study of THC/CBD oromucosal spray medication, al-
though there was no significant difference in pain scores, the
patient global impression of change showed a significant
difference between groups.4 We are hypothesizing that any
benefit of medicinal cannabis may be in holistic well-being
rather than limited to a single symptom. This study has
demonstrated that ESAS TSDS is a feasible and practical
measure to assess participant change in symptom distress
over time. It has also confirmed the benefit of including
emotional well-being subscales.
The major limitations of this study are the small sample
size and lack of placebo. The participants were heteroge-
neous and had complex clinical pictures consistent with their
advanced disease and various treatment protocols. Although
the median baseline performance status of participants was
high (median AKPS 70), the median survival of around five
months demonstrates that most patients enrolled had a poor
prognosis and clearly fitted the definition of palliative care.
This study has shown that trials of medicinal cannabis in
advanced cancer patients undergoing palliative care are fea-
sible. The doses of THC and CBD used in this study were
generally well tolerated and the outcome measure of ESAS
TSDS is promising as a measure of overall symptom benefit.
However, these results need to be replicated within a placebo-
controlled trial to test the true effect of medicinal cannabis in
this patient population. With the current state of knowledge,
we suggest that medicinal cannabis in this patient population
should always be prescribed within the context of a clinical
trial or through prospective data collection, whereby efficacy
and side effects can be monitored in a controlled manner.
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Table 2. Changes in Scores for Individual Edmonton Symptom Assessment Scale Items
from Days 0 to 14 (n = 18)
Variable Mean change (95% CI) Median (IQR change) Range
Pain -0.61 (-1.78 to 0.56) -1.0 (-2.0 to 0.0) -6 to 4
Tiredness -0.17 (-1.50 to 1.17) 0.0 (-1.0 to 1.0) -8 to 6
Nausea -0.56 (-1.91 to 0.79) -0.5 (-3.0 to 1.0) -5 to 6
Shortness of breath -0.5 (-1.59 to 0.59) 0.0 (-2.0 to 0.0) -4 to 4
Drowsiness 0.22 (-0.92 to 1.37) 0.5 (-1.0 to 1.0) -4 to 5
Appetite -0.94 (-1.90 to 0.01) -1.0 (-2.0 to 1.0) -4 to 2
Anxiety -1.61 (-2.92 to -0.30)* -1.0 (-4.0 to 0.0) -7 to 3
Depression -1.33 (-2.50 to -0.16)** -1.0 (-2.0 to 0.0) -8 to 3




Table 3. Number of Adverse Events Graded












Confusion 2 1 1 4




Paranoia 1 1 2
Anxiety 2 2 1 5
Mood 1 3 2 6
Psychosis 0
Hypertension 1 3 2 6
Tachycardia 2 1 1 4
Sweating 1 1 2
Nausea 3 4 7
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